CCA
VIVO

Catalyst Capital Advisors’s Meridian Bioscience Inc VIVO Stock Holding History

Catalyst Capital Advisors’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-29,500
Closed -$608K – 571
2016
Q1 		$608K Buy
+29,500
New +$581K 0.1% 159

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Catalyst Capital Advisors's VIVO Position: Q2 2016 in Review

Catalyst Capital Advisors sold out of Meridian Bioscience Inc (VIVO) in Q2 2016, closing a stake of 29,500 shares — an estimated $608K sold.

Catalyst Capital Advisors first reported a position in VIVO in Q1 2016 and held it in 1 quarter. The position peaked at $608K in Q1 2016. 180 funds tracked by Wall St. Rank hold VIVO as of Q2 2016.

  • Catalyst Capital Advisors reported no remaining Meridian Bioscience Inc position as of Q2 2016 after selling out during the quarter.
  • Catalyst Capital Advisors sold 29,500 Meridian Bioscience Inc shares in Q2 2016, an estimated $608K.
  • Catalyst Capital Advisors first reported a position in Meridian Bioscience Inc in Q1 2016 and held it in 1 quarter.
  • Catalyst Capital Advisors's Meridian Bioscience Inc position peaked at $608K in Q1 2016.
  • 180 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2016.

Based on Catalyst Capital Advisors's 13F filing for Q2 2016, filed 10 Aug 2016.